Categories
- PROTAC Linker
- Protein Control Ligand
- Pathway Inhibitors
- Function Modulators
- Activators
- G Protein-Coupled Receptor Ligands
- Nuclear Receptor Ligands
- GDNF Receptors
- TNF Receptors
- Transcription Factors
- Chemokines
- Cytokine Receptors
- Biomarkers and Buffer Solutions
- Molecular Probes
- Stem Cell Research
- Alzheimer's Disease
- Apoptosis
- Cancer Research
- Epigenetics
- Metabolites
- PET/SPECT Imaging Precursors
- Customized Screening Library
- Ultra Pure Pharmacological Standard
- Tissue Microarray (TMA)
- Proteins and Antibodies
- Primary Cells
- ELISA KIT
- Natural Products
- Lab Equipments
- Humanized Mice for PDX Platform
- Rare Chemicals
- Custom Synthesis
- Antibacterial
- Antifungal
- Antioxidant
- Antiviral
- Molecular Glues
- SARS-CoV
Quantity Discount Table - Order More To Get More Price Discount
| Quantity | mg | Unit Price ($/mg or $/Unit) | Final Price |
|---|---|---|---|
| 1 | 5 | $68.00 | Total: $340.00 |
| 1 | 10 | $57.60 | Total: $576.00 |
| 1 | 25 | $48.80 | Total: $1,220.00 |
| 1 | 50 | $41.60 | Total: $2,080.00 |
| 1 | 100 | $36.00 | Total: $3,600.00 |
Overview
Rilapladib (SB 659032) is a selective inhibitor of Lipoprotein-Associated Phospholipase A2 (Lp-PLA2, IC50 = 230 pM) and acts as an antagonist of the platelet-activating factor receptor.
Chemical Properties
| Molecular Formula | C40H38F5N3O3S |
| Molecular Weight | 735.8 |
| CAS Numbers | 412950-08-4 |
| Solubility | DMSO |
| Purity | 98% by HPLC |
| SMILES Code | COCCN1CCC(CC1)N(Cc1ccc(cc1)-c1ccc(cc1)C(F)(F)F)C(=O)Cn1c(SCc2cccc(F)c2F)cc(=O)c2ccccc12 |
Storage and Handling
0C Short Term, -20C Long Term
References
Shaddinger BC, et al. Platelet aggregation unchanged by lipoprotein-associated phospholipase A? inhibition results from an in vitro study and two randomized phase I trials. PLoS One. 2014 Jan 27;9[1] e83094.